Sponsored Clinical and Research Opportunities for Patients

Below you will find sponsored clinical trial and research opportunities available to the pulmonary hypertension community. For a complete list of clinical trials, visit PHA Clinical Trial Finder or ClinicalTrials.gov. To learn more about research and clinical trials, visit PHAssociation.org/Research.

Prospective Collection of Biospecimen Samples in Participants Diagnosed with Pulmonary Arterial Hypertension

Population: ages 18 to 85

Start Date: March 27, 2023

End Date: July 31, 2023

Phase: Preclinical

Institution: Sanguine Biosciences

Study Website: https://patients.sanguinebio.com/pah/

Study Summary

The goal of this research is to identify non-invasive biomarkers associated with pulmonary arterial hypertension and to compare the biomarkers between patients and across time.

A Study of the Efficacy and Safety of MK-5475 in Participants with Pulmonary Arterial Hypertension

Population: Pulmonary Arterial Hypertension in adults ages 18-75 years old (inclusive)

Start Date: May 19, 2021

End Date: February 9, 2026

Phase: Phase 2/Phase 3

Institution: Multi-center

Study Website: https://www.INSIGNIA-PAHstudy.com

Study Summary

The INSIGNIA-PAH Clinical Trial will test an investigational drug in adults ages 18 to 75 who have pulmonary arterial hypertension (PAH). PAH is a type of high blood pressure that affects arteries in the lungs and the right side of the heart. This clinical trial is comparing the investigational drug with a placebo, both of which are a dry powder. A placebo looks like the investigational trial drug but does not contain any active medicine. You will breathe the powder into your lungs from your mouth through an inhaler.

Researchers want to:

Learn about the safety of the investigational drug and how well participants tolerate side effects associated with the investigational drug
Find the dose of the investigational drug that should be given to participants

The trial has four parts: screening (up to 4 weeks long), trial treatment base period (about 12 weeks long), an optional trial treatment extension period and participants will receive the trial drug (about 2 years long), and a follow up phone call (about 2 weeks after you stop taking the trial drug).

A Phase 2/3 trial: Currently this study is enrolling our Phase 2 part of the trial. In Phase 2, we will research the investigational drug to determine the appropriate amount of drug to give to participants.

The Phase 3 part of the trial is not currently enrolling. Phase 3 clinical trials compare the safety and effectiveness of the investigational drug against the current standard treatment. Each phase of this trial includes a Base Period and an Extension Period.

To learn more or to participate in the INSIGNIA-PAH clinical trial, you can visit INSIGNIA-PAHstudy.com or clinicaltrials.gov.

There is a lot to consider when deciding whether to participate in a clinical trial. Any clinical trial includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.

These opportunities are not affiliated with, endorsed by, or supported by the Pulmonary Hypertension Association or its affiliates (collectively, “PHA”). Participation in these opportunities do not affect your relationship with PHA or its entities. Information obtained by companies or researchers is not shared with PHA or any of its PH-accredited Care Center programs.

Sponsored Clinical and Research Opportunities for Patients

Prospective Collection of Biospecimen Samples in Participants Diagnosed with Pulmonary Arterial Hypertension

Study Summary

A Study of the Efficacy and Safety of MK-5475 in Participants with Pulmonary Arterial Hypertension

Study Summary

Title